Mouraviev, V., Mayes, J. M., Jackson, L., Stein, A. J., Haystead, T., Vujaskovic, Z., & Polascik, T. J. (2008). NEOADJUVANT DOCETAXEL WITH SUBSEQUENT CYOABLATION OF AN AGGRESSIVE RM-9 MURINE PROSTATE CANCER MODEL IS ASSOCIATED WITH DECREASE IN INTERSTITIAL FLUID PRESSURE AND IMPROVEMENT OF OXYGENATION. In Journal of Urology (Vol. 179, pp. 420–420). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1016/s0022-5347(08)61231-8

Mouraviev, Vladimir, Janice M. Mayes, Laurean Jackson, Alexandra J. Stein, Timothy Haystead, Zeljko Vujaskovic, and Thomas J. Polascik. “NEOADJUVANT DOCETAXEL WITH SUBSEQUENT CYOABLATION OF AN AGGRESSIVE RM-9 MURINE PROSTATE CANCER MODEL IS ASSOCIATED WITH DECREASE IN INTERSTITIAL FLUID PRESSURE AND IMPROVEMENT OF OXYGENATION.” In Journal of Urology, 179:420–420. Ovid Technologies (Wolters Kluwer Health), 2008. https://doi.org/10.1016/s0022-5347(08)61231-8.

Mouraviev V, Mayes JM, Jackson L, Stein AJ, Haystead T, Vujaskovic Z, et al. NEOADJUVANT DOCETAXEL WITH SUBSEQUENT CYOABLATION OF AN AGGRESSIVE RM-9 MURINE PROSTATE CANCER MODEL IS ASSOCIATED WITH DECREASE IN INTERSTITIAL FLUID PRESSURE AND IMPROVEMENT OF OXYGENATION. In: Journal of Urology. Ovid Technologies (Wolters Kluwer Health); 2008. p. 420–420.

Mouraviev, Vladimir, et al. “NEOADJUVANT DOCETAXEL WITH SUBSEQUENT CYOABLATION OF AN AGGRESSIVE RM-9 MURINE PROSTATE CANCER MODEL IS ASSOCIATED WITH DECREASE IN INTERSTITIAL FLUID PRESSURE AND IMPROVEMENT OF OXYGENATION.” Journal of Urology, vol. 179, no. 4S, Ovid Technologies (Wolters Kluwer Health), 2008, pp. 420–420. Crossref, doi:10.1016/s0022-5347(08)61231-8.

Mouraviev V, Mayes JM, Jackson L, Stein AJ, Haystead T, Vujaskovic Z, Polascik TJ. NEOADJUVANT DOCETAXEL WITH SUBSEQUENT CYOABLATION OF AN AGGRESSIVE RM-9 MURINE PROSTATE CANCER MODEL IS ASSOCIATED WITH DECREASE IN INTERSTITIAL FLUID PRESSURE AND IMPROVEMENT OF OXYGENATION. Journal of Urology. Ovid Technologies (Wolters Kluwer Health); 2008. p. 420–420.